The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia (Q82464040)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

main subject

acute myeloid leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Hsin-An Hou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jih-Luh Tang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Ming Yao

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Kuan-Ting Kuo

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Tien Hwei-fang

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

W-C Lei

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

B-S Ko

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

C-Y Chen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

W Tsay

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S-J Wu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S-Y Huang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S-C Hsu

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Y-C Chen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Y-C Chang

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

F-Y Lee

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

M-C Liu

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

C-W Liu

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

M-H Tseng

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

C-F Huang

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

16 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

246-253

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21079611%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2010.267

16 January 2020

exact match

0 references

cites work

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

IDH1 mutations in gliomas: when an enzyme loses its grip

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Recurring mutations found by sequencing an acute myeloid leukemia genome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

The effects of calcium ions and adenine nucleotides on the activity of pig heart 2-oxoglutarate dehydrogenase complex

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Reactive oxygen species in cancer cells: live by the sword, die by the sword.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021

Therapy insight: Potential of statins for cancer chemoprevention and therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.267

7 January 2021